Summary & Overview
CPT 0898T: Prostate Cancer AI Mapping and Margin Assessment
CPT code 0898T covers an AI-driven, noninvasive service that creates a visual map estimating prostate cancer location and extent, including margin determination and a physician’s interpretation and report. This code represents a growing class of diagnostic-augmentation technologies that combine imaging and pathology data to inform surgical planning, focal therapies, and risk stratification.
Nationally, adoption of AI-enabled diagnostic mapping affects clinical workflows in urology, radiation oncology, and radiology and has implications for coverage policies, coding guidance, and reimbursement frameworks across public and private payers. Key payers examined in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what CPT code 0898T represents, how the service is typically delivered, and why it matters for care coordination and procedural planning. The publication summarizes payer coverage patterns and benchmark considerations, clarifies the clinical context for use (imaging- and pathology-integrated prostate cancer localization and margin assessment), and highlights policy and coding issues that influence uptake and billing practices. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0898T describes a noninvasive, artificial intelligence (AI)–based mapping service that estimates the extent and location of prostate cancer by analyzing patient imaging and pathology results. The technology produces a visual map indicating how far cancer has extended within the prostate, includes margin determination, and requires a physician interpretation and written report.
Service type: Image- and data-driven cancer localization and margin assessment using AI
Typical site of service: Outpatient imaging or radiology setting, ambulatory surgical center, or clinic where imaging and pathology data are available for noninvasive interpretation
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 67-year-old man with newly diagnosed, biopsy-proven prostate adenocarcinoma is referred for treatment planning. Multiparametric prostate MRI and prior transrectal ultrasound–guided biopsy results are available. The treating urologist orders an AI‑based, noninvasive mapping service to estimate tumor extent within the prostate, determine likely surgical or radiotherapy margins, and guide targeted biopsy or focal therapy. The imaging and pathology datasets are uploaded to the AI platform, which fuses MRI anatomy with biopsy core locations and histopathology to generate a visual prostate cancer map. A radiologist or urologist with appropriate credentialing reviews the AI output, documents margin determinations, interprets the findings, and issues a formal report to the referring clinician. Typical workflow steps: image and pathology data acquisition → secure upload to AI platform → automated map generation → physician review and interpretation → report delivery integrated into the electronic health record. Typical sites of service include outpatient imaging centers, hospital outpatient departments, and urology clinics that coordinate advanced imaging review and treatment planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the physician interpretation and report separate from technical component. |
TC | Technical component | Use when reporting only the technical processing, software, or image generation without physician interpretation. |
22 | Increased procedural services | Use when the physician time, complexity, or work required for interpretation substantially exceeds typical service. |
52 | Reduced services | Use when the service is partially reduced or not completed as originally planned. |
53 | Discontinued procedure | Use when the service is started but terminated due to patient or clinical circumstances. |
62 | Two surgeons | Use when two surgeons of different specialties share responsibility for intraoperative management related to findings (rare for this consultative mapping service). |
78 | Unplanned return to operating/procedure room | Use when findings directly lead to an immediate unplanned operative procedure. |
80 | Assistant at surgery | Use if a surgical assistant documents services related to management guided by the map and billing rules apply. |
82 | Assistant not available | Use when an assistant is required but not available and the service documentation supports the modifier. |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services | Use to identify services furnished by these midlevel practitioners as allowed by payer policy. |
73 | Discontinued outpatient hospital/ambulatory surgery before anesthesia | Use if the mapping workflow or related procedure is cancelled before anesthesia or procedural sedation. |
53 | Discontinued procedure | Duplicate entry avoided; see single use above. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 208000000X | Urology | Urologists commonly order and interpret mapping output for surgical planning. |
| 207RG0100X | Radiology | Diagnostic radiologists perform MRI interpretation and integrate imaging data with AI maps. |
| 2084P0800X | Radiation Oncology | Radiation oncologists use the map to plan target volumes and margins for radiotherapy. |
| 363L00000X | Clinical Laboratory/Pathology (Anatomic & Clinical Pathology) | Pathologists contribute biopsy pathology data and correlate histologic findings with mapping output. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C61 | Malignant neoplasm of prostate | Primary diagnosis for which AI mapping is performed to localize tumor extent and plan treatment. |
D07.5 | Carcinoma in situ of prostate | High-grade intraepithelial neoplasia or in situ changes may prompt enhanced mapping to assess risk and margins. |
N40 | Benign prostatic hyperplasia | Coexisting BPH can affect imaging appearance and interpretation; mapping helps distinguish benign from malignant regions. |
R33.9 | Retention of urine, unspecified | Urinary retention symptoms may be present in prostate disease evaluation and can influence management planning. |
Z85.46 | Personal history of malignant neoplasm of prostate | Relevant for surveillance workflows where mapping monitors recurrence or residual disease. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
55700 | Transurethral resection of prostate, including control of postoperative bleeding, when performed | Prior or subsequent surgical treatment for obstructive disease; not directly part of mapping but may be relevant in surgical workflows. |
76872 | Transrectal ultrasound, prostate, including guidance for needle placement | Commonly used to localize biopsy cores that are integrated into the AI mapping process. |
88305 | Level IV surgical pathology, gross and microscopic examination | Histopathology of prostate biopsy cores that provides diagnostic input to the mapping algorithm. |
72197 | Magnetic resonance (eg, prostate) with contrast and spectroscopy when performed — pelvic MRI codes vary; use appropriate MRI pelvis-prostate code per payer | Multiparametric prostate MRI provides the imaging data fused into the AI map. |
77301 | Radiation treatment planning, simulation; basic dosimetry, simple | Radiation oncology planning codes used after map interpretation to define treatment volumes and margins. |